BRAF and lung carcinoma: Moreover, sensitivity to erastin-induced ferroptosis was also reduced in shRNA-mediated KRAS-silenced Calu-1 lung cancer cells, and inhibition of BRAF activity was also found to reduce sensitivity to erastin in BRAF-silenced A-673 cells [16].